Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang · 2023
Read Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis by Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10750407.txt.
Description
Shuhui You and co-authors compare two drug pairs for HER2 positive breast cancer that has spread in a 2023 study. Both pairs join trastuzumab with a second drug that targets the same growth signal, either pyrotinib or pertuzumab. Records came from five centers in China for 333 patients treated between 2017 and 2022.
In first line use, the pertuzumab pair showed a longer time before the cancer grew, though the gap was near the edge of certainty. In later lines the pairs were much the same. Across all patients the pertuzumab pair looked better at first, but it was not an independent factor once other traits were weighed. Without one drug class, the pyrotinib pair did better.
Catalog record
| CREATOR | Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |